Recent workflow advances and novel applications in volumetric microsampling supporting quantitative bioanalysis

A rational approach to device selection is proposed alongside small and large molecule case studies exemplifying novel workflows that eliminate HCT bias, optimize sensitivity and stabilize labile analytes.

In this webinar, an experimental strategy is introduced that aids in microsampling device selection based upon key bioanalytical drivers that consider the relationship between blood hematocrit, collection substrate (rigid porous polymer vs. cellulose), analyte stability and age-related extractability. Exemplary case studies highlighting novel microsampling workflows are then presented for (i) an anti-tuberculosis drug panel requiring pre-treatment of Capitainer®B cellulose substrate to stabilize three reactive analytes and (ii) Fomivirsen, a 21-mer antisense oligonucleotide and its N-1 metabolite, wherein high-yielding extractability with surfactant in a comparability study of Mitra VAMS and Capitainer®B necessitated a hybridization LC-MS/MS approach to overcome matrix complexities.

Of interest to:

• Scientists developing and validating methods for small and large molecules extracted from dried blood microsamples
• Clinical researchers and key decision makers involved with microsampling device selection
• Biotech and Pharma groups leveraging microsampling to facilitate drug development
• Investigators exploring the patient-centric approach to sample collection
• Microsampling manufacturers interested in real world applications and device performance

What you will learn

• A bioanalytical-driven strategy for microsample device selection
• Extraction techniques to overcome HCT-induced recovery bias and age-related extractability
• Approaches for stabilization of labile analytes via substrate pre-treatment
• Workflows for extraction and analysis of antisense oligonucleotides from dried blood microsamples
• Evaluations required for validation of microsampling assays in the regulated space